Thomas Carl Krivak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thomas Carl Krivak has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Chunqiao Tian
Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY 14263
4 shared publicationsKathleen M. Darcy
Womens Health Integrated Research Center at Inova Health System, 3289 Woodburn Road, Annandale, VA 22003, USA
4 shared publicationsJulie A. DeLoia
School of Public Health and Health Services, The George Washington University, NW, Washington, DC 20037, USA
3 shared publications- Chad A. Hamilton
Gynecologic Oncology Service, Department of Obstetrics and Gynecology, Walter Reed National Military Medical Center, Bethesda, MD, USA
2 shared publications Christine B. Ambrosone
2 shared publicationsDeborah K. Armstrong
John Hopkins Kimmel Cancer Center, Baltimore, MD 21231
2 shared publications
Latest Publications
- 1 June 2015
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 70 (6) , 390-392
Does Aggressive Surgery Improve Outcomes? Interaction Between Preoperative Disease Burden and Complex Surgery in Patients With Advanced-Stage Ovarian Cancer
Most patients with epithelial ovarian cancer (EOC) are diagnosed at an advanced stage, and 5-year survival is low. Initial management includes primary debulking surgery (PDS) followed by adjuvant platinum and taxane-based chemotherapy. A large number of studies have shown a survival benefit for patients with advanced EOC after PDS from both optimal debulking (P < 0.01; OS, 41 vs 77 months; P < 0.01). Patients with high preoperative disease burden (DS high) had shorter PFS and OS than did those with DS moderate or low (PFS, 15 vs 23 or 34 months [P < 0.01]; OS, 40 vs 71 or 86 months [P < 0.01], respectively). This relationship was maintained in the subset of R0 patients with PFS (18 vs 33 months; DS moderate or low: P < 0.001) and OS (50 vs 83 months; DS moderate or low: P < 0.001). Complexity score was not an independent prognostic indicator of either PFS or OS after controlling for DS, as well as performance status, age, and cell type. These data show that initial disease burden remains a significant prognostic indicator for PFS and OS despite R0. Survival is not improved by complex surgery after adjusting for confounding influences, especially residual disease.
- 1 June 2015
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 70 (6) , 390-392
Does Aggressive Surgery Improve Outcomes? Interaction Between Preoperative Disease Burden and Complex Surgery in Patients With Advanced-Stage Ovarian Cancer
Most patients with epithelial ovarian cancer (EOC) are diagnosed at an advanced stage, and 5-year survival is low. Initial management includes primary debulking surgery (PDS) followed by adjuvant platinum and taxane-based chemotherapy. A large number of studies have shown a survival benefit for patients with advanced EOC after PDS from both optimal debulking (P < 0.01; OS, 41 vs 77 months; P < 0.01). Patients with high preoperative disease burden (DS high) had shorter PFS and OS than did those with DS moderate or low (PFS, 15 vs 23 or 34 months [P < 0.01]; OS, 40 vs 71 or 86 months [P < 0.01], respectively). This relationship was maintained in the subset of R0 patients with PFS (18 vs 33 months; DS moderate or low: P < 0.001) and OS (50 vs 83 months; DS moderate or low: P < 0.001). Complexity score was not an independent prognostic indicator of either PFS or OS after controlling for DS, as well as performance status, age, and cell type. These data show that initial disease burden remains a significant prognostic indicator for PFS and OS despite R0. Survival is not improved by complex surgery after adjusting for confounding influences, especially residual disease.
- Open Access
- 5 March 2013
- Published by Springer Nature in British Journal of Cancer
- Vol. 108 (6) , 1231-1237
BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study
Background: Methods: Results: Conclusion:
- 5 March 2013
- Published by Springer Nature in British Journal of Cancer
- Vol. 108 (6) , 1231-1237
Open AccessBRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study
Background: Methods: Results: Conclusion:
- 1 September 2012
- Published by Elsevier in Gynecologic Oncology
- Vol. 126 (3) , 448-454
Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum
- 1 September 2012
- Published by Elsevier in Gynecologic Oncology
- Vol. 126 (3) , 448-454
Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum
- 1 May 2012
- Published by Elsevier in Gynecologic Oncology
- Vol. 125 (2) , 421-426
Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: A gynecologic oncology group study
- 1 May 2012
- Published by Elsevier in Gynecologic Oncology
- Vol. 125 (2) , 421-426
Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: A gynecologic oncology group study
- 31 December 2011
- Published by Elsevier in Gynecologic Oncology
- Vol. 123 (3) , 616
Re: Implications of upper abdominal disease in advanced ovarian cancer after surgical cytoreduction and relation with tumor biology
- 31 December 2011
- Published by Elsevier in Gynecologic Oncology
- Vol. 123 (3) , 616
Re: Implications of upper abdominal disease in advanced ovarian cancer after surgical cytoreduction and relation with tumor biology
- 1 October 2009
- Published by Elsevier in Gynecologic Oncology
- Vol. 115 (1) , 81-85
A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: An analysis of patients enrolled in GOG 172
- 1 October 2009
- Published by Elsevier in Gynecologic Oncology
- Vol. 115 (1) , 81-85
A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: An analysis of patients enrolled in GOG 172
- 20 July 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (21) , 3598-3606
Relationship BetweenERCC1Polymorphisms, Disease Progression, and Survival in the Gynecologic Oncology Group Phase III Trial of Intraperitoneal Versus Intravenous Cisplatin and Paclitaxel for Stage III Epithelial Ovarian Cancer
Purpose: We hypothesized that common polymorphisms in excision repair cross-complementation group 1 (ERCC1), involved in nucleotide excision repair of platinum-induced damage, would be associated with progression-free survival (PFS) and overall survival (OS) in women with optimally resected, stage III epithelial ovarian cancer (EOC) treated with cisplatin and paclitaxel (C+P).Patients and Methods: Single nucleotide polymorphism analysis was carried out by direct pyrosequencing at two sites (codon 118 and C8092A) in ERCC1 in leukocyte DNA from women who participated in the Gynecologic Oncology Group (GOG) phase III protocol-172 and were randomly assigned to intraperitoneal or intravenous C+P.Results: ERCC1 genotyping was performed in 233 of the 429 women who participated in GOG-172. The genotype distribution at codon 118 was 17% with C/C, 43% with C/T, and 40% with T/T, and the genotype distribution at C8092A was 56% with C/C, 37% with C/A, and 7% with A/A. Adjusted Cox regression analysis revealed that the codon 118 polymorphism in ERCC1 was not significantly associated with disease progression or death. Women with the C8092A C/A or A/A genotypes compared with the C/C genotype had an increased risk of disease progression (hazard ratio [HR] = 1.44; 95% CI, 1.06 to 1.94; P = .018) and death (HR = 1.50; 95% CI, 1.07 to 2.09; P = .018). Median PFS and OS were 6 and 17 months shorter for women with the C8092A C/A or A/A genotypes versus the C/C genotype, respectively.Conclusion: Although the ERCC1 codon 118 polymorphism does not seem to be associated with clinical outcome, the C8092A polymorphism was an independent predictor of PFS and OS in women with optimally resected EOC.
- 20 July 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (21) , 3598-3606
Relationship BetweenERCC1Polymorphisms, Disease Progression, and Survival in the Gynecologic Oncology Group Phase III Trial of Intraperitoneal Versus Intravenous Cisplatin and Paclitaxel for Stage III Epithelial Ovarian Cancer
Purpose: We hypothesized that common polymorphisms in excision repair cross-complementation group 1 (ERCC1), involved in nucleotide excision repair of platinum-induced damage, would be associated with progression-free survival (PFS) and overall survival (OS) in women with optimally resected, stage III epithelial ovarian cancer (EOC) treated with cisplatin and paclitaxel (C+P).Patients and Methods: Single nucleotide polymorphism analysis was carried out by direct pyrosequencing at two sites (codon 118 and C8092A) in ERCC1 in leukocyte DNA from women who participated in the Gynecologic Oncology Group (GOG) phase III protocol-172 and were randomly assigned to intraperitoneal or intravenous C+P.Results: ERCC1 genotyping was performed in 233 of the 429 women who participated in GOG-172. The genotype distribution at codon 118 was 17% with C/C, 43% with C/T, and 40% with T/T, and the genotype distribution at C8092A was 56% with C/C, 37% with C/A, and 7% with A/A. Adjusted Cox regression analysis revealed that the codon 118 polymorphism in ERCC1 was not significantly associated with disease progression or death. Women with the C8092A C/A or A/A genotypes compared with the C/C genotype had an increased risk of disease progression (hazard ratio [HR] = 1.44; 95% CI, 1.06 to 1.94; P = .018) and death (HR = 1.50; 95% CI, 1.07 to 2.09; P = .018). Median PFS and OS were 6 and 17 months shorter for women with the C8092A C/A or A/A genotypes versus the C/C genotype, respectively.Conclusion: Although the ERCC1 codon 118 polymorphism does not seem to be associated with clinical outcome, the C8092A polymorphism was an independent predictor of PFS and OS in women with optimally resected EOC.
- 1 August 2007
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 110 (2) , 477-479
Pregnancy After Tumor Debulking and Intraperitoneal Cisplatin for Appendiceal Carcinoid Tumor
Pregnancy after cytoreductive surgery and intraperitoneal chemotherapy is rare. We present the case of a 25-year-old woman with appendiceal carcinoid tumor treated with intraperitoneal cisplatin for peritoneal recurrence after a fertility-sparing cytoreductive procedure. Five years after her procedure, she conceived with the help of assisted reproductive technologies and delivered a viable term fetus via cesarean delivery. She subsequently had a successful second pregnancy and is currently alive without evidence of her disease. Conception is possible after tumor debulking and intraperitoneal chemotherapy. In unique clinical situations, fertility-sparing surgery may be considered in young patients who desire future pregnancy.
- 1 August 2007
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 110 (2) , 477-479
Pregnancy After Tumor Debulking and Intraperitoneal Cisplatin for Appendiceal Carcinoid Tumor
Pregnancy after cytoreductive surgery and intraperitoneal chemotherapy is rare. We present the case of a 25-year-old woman with appendiceal carcinoid tumor treated with intraperitoneal cisplatin for peritoneal recurrence after a fertility-sparing cytoreductive procedure. Five years after her procedure, she conceived with the help of assisted reproductive technologies and delivered a viable term fetus via cesarean delivery. She subsequently had a successful second pregnancy and is currently alive without evidence of her disease. Conception is possible after tumor debulking and intraperitoneal chemotherapy. In unique clinical situations, fertility-sparing surgery may be considered in young patients who desire future pregnancy.
- 1 March 2007
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 109 (3) , 761-777
Venous Thromboembolism in Obstetrics and Gynecology
The diagnosis of venous thromboembolism can present a clinical challenge. Using D-dimer testing and spiral or helical computed tomography scans has simplified the diagnosis of venous thromboembolism. In addition, the use of low molecular weight heparin has become widely accepted in the prevention and treatment of venous thromboembolism. However, further studies are needed to determine optimal prevention and treatment strategies, particularly in the obstetric population.
- 1 March 2007
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 109 (3) , 761-777
Venous Thromboembolism in Obstetrics and Gynecology
The diagnosis of venous thromboembolism can present a clinical challenge. Using D-dimer testing and spiral or helical computed tomography scans has simplified the diagnosis of venous thromboembolism. In addition, the use of low molecular weight heparin has become widely accepted in the prevention and treatment of venous thromboembolism. However, further studies are needed to determine optimal prevention and treatment strategies, particularly in the obstetric population.